ECSP055576A - Uso de derivados de ciclotiocarbamato en el tratamiento de las condiciones relacionadas con hormonas - Google Patents

Uso de derivados de ciclotiocarbamato en el tratamiento de las condiciones relacionadas con hormonas

Info

Publication number
ECSP055576A
ECSP055576A EC2005005576A ECSP055576A ECSP055576A EC SP055576 A ECSP055576 A EC SP055576A EC 2005005576 A EC2005005576 A EC 2005005576A EC SP055576 A ECSP055576 A EC SP055576A EC SP055576 A ECSP055576 A EC SP055576A
Authority
EC
Ecuador
Prior art keywords
formula
administration
cyclotiocarbamate
hormones
derivatives
Prior art date
Application number
EC2005005576A
Other languages
English (en)
Inventor
Andrew Fensome
Gary Grubb
Diane Deborah Harrison
Richarg Craing Winneker
Puwen Zhang
Jeffrey Curtis Kern
Eugene Anthony Terefenko
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP055576A publication Critical patent/ECSP055576A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona métodos para inducir contracepción, el cual incluye la administración a una fémina de una composición que contiene un compuesto de fórmula I, fórmula II o tautómeros de los mismos, en un régimen el cual involucra la administración de uno o más de un modulador del receptor de estrógenos selectivo, donde la fórmula I es: (I) y donde R1-R5 y Q1 son definidos como se describe aquí. Se describen métodos para proveer terapia de re-emplazo hormonal y para tratar carcinomas, sangramiento disfuncional, leiomiomata uterino y síndrome del ovario poliquístico, los cuales incluyen la administración de un compuesto de fórmula I o fórmula II y un modulador del receptor de estrógenos selectivo.
EC2005005576A 2002-06-25 2005-01-25 Uso de derivados de ciclotiocarbamato en el tratamiento de las condiciones relacionadas con hormonas ECSP055576A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39187102P 2002-06-25 2002-06-25

Publications (1)

Publication Number Publication Date
ECSP055576A true ECSP055576A (es) 2005-04-18

Family

ID=30000766

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005576A ECSP055576A (es) 2002-06-25 2005-01-25 Uso de derivados de ciclotiocarbamato en el tratamiento de las condiciones relacionadas con hormonas

Country Status (19)

Country Link
US (1) US7192956B2 (es)
EP (1) EP1515725A4 (es)
JP (1) JP2005535624A (es)
KR (1) KR20050013247A (es)
CN (1) CN1662241A (es)
AR (1) AR040333A1 (es)
AU (1) AU2003247608A1 (es)
BR (1) BR0312024A (es)
CA (1) CA2489847A1 (es)
CO (1) CO5680438A2 (es)
CR (1) CR7611A (es)
EC (1) ECSP055576A (es)
IL (1) IL165396A0 (es)
MX (1) MXPA04012421A (es)
NO (1) NO20045216L (es)
RU (1) RU2005101638A (es)
TW (1) TW200404548A (es)
WO (1) WO2004000801A2 (es)
ZA (1) ZA200410411B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
TW200407124A (en) * 2002-06-25 2004-05-16 Wyeth Corp Use of thio-oxindole derivatives in treatment of hormone-related conditions
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
AU2005233648B2 (en) * 2004-04-08 2011-06-23 Wyeth Methods for minimizing thioamide impurities
ES2317223T3 (es) * 2004-04-08 2009-04-16 Wyeth Derivados de tioamida como moduladores del receptor de progesterona.
MXPA06012402A (es) * 2004-04-27 2007-01-17 Wyeth Corp Carbamato y tiocarbamato biarilos ciclicos que contienen cianopirrol y metodos para preparar los mismos.
CA2575737C (en) * 2004-08-13 2013-09-24 Wyeth Tanaproget derivatives, metabolites, and uses thereof
US7399766B2 (en) * 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
CN101027321A (zh) * 2004-08-20 2007-08-29 惠氏公司 孕酮受体结构
ATE460937T1 (de) * 2005-04-28 2010-04-15 Wyeth Corp Mikronisierte tanaproget zusammensetzungen und verfahren zu ihrer herstellung
EP1877059B8 (en) 2005-04-28 2010-05-19 Wyeth a Corporation of the State of Delaware Micronized tanaproget and compostions containing same
BRPI0610156A2 (pt) * 2005-04-28 2016-08-16 Wyeth Corp forma micronizada de um composto, forma purificada i do composto, kit, padrão de referência, e, método de preparaçao de uma composição farmacêutica.
AU2011226814B2 (en) * 2005-04-28 2013-06-13 Wyeth Llc Micronized tanaproget, compositions, and methods of preparing the same
AU2011203520B2 (en) * 2005-04-28 2012-06-14 Wyeth Micronized tanaproget and compostions containing same
DE602006007453D1 (de) * 2005-04-28 2009-08-06 Wyeth Corp Zusammensetzungen mit mikronisiertem tanaproget
CN101166736B (zh) * 2005-04-28 2013-02-06 惠氏公司 他那普戈特的多晶型ⅱ
CN101193639A (zh) * 2005-06-09 2008-06-04 惠氏公司 含有炔雌醇的tanaproget组合物
CA2672835A1 (en) * 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Processes for the preparation of (3r, 4r) -n- (4-chlorophenyl) -1- (2, 2-difluoroethyl) -n'- [2-fluoro-4- (2-oxo-1 (2h) -pyridinyl) phenyl] -3 , 4-pyrrolidinedicarboxamide
US20090170823A1 (en) * 2007-12-20 2009-07-02 Duramed Pharmaceuticals, Inc. Dosage Regimens and Pharmaceutical Compositions and Packages for Emergency Contraception
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
EP2475366A1 (en) * 2009-09-11 2012-07-18 Bayer Pharma Aktiengesellschaft Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
ES2627692T3 (es) 2010-06-10 2017-07-31 Aragon Pharmaceuticals, Inc. Moduladores de receptores de estrógenos y usos de los mismos
SG11201403002RA (en) 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof
US20170014174A1 (en) * 2015-07-17 2017-01-19 Candela Corporation Cryogenic Cylinder

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
WO1985000519A1 (en) 1983-07-29 1985-02-14 Duke University Method of treating androgen-related disorders
GB2310660A (en) 1996-03-01 1997-09-03 Merck & Co Inc Benzoxazinone oxytocin receptor antagonists
US6653297B1 (en) * 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
US6326392B1 (en) * 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
ES2258342T3 (es) 1998-10-23 2006-08-16 Aventis Pharma S.A. Preparaciones para aplicacion topica de sustancias que tienen efecto antiandrogenico.
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6258802B1 (en) * 1999-10-06 2001-07-10 Medical College Of Hampton Roads Corticoid therapy
WO2001030356A1 (fr) * 1999-10-25 2001-05-03 Laboratoire Theramex Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
US20010034340A1 (en) * 2000-03-20 2001-10-25 American Home Products Corporation Hormone replacement therapy
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
GB0010683D0 (en) * 2000-05-03 2000-06-28 Univ Bristol Cancer therapy
FR2814074B1 (fr) * 2000-09-15 2003-03-07 Theramex Nouvelles compositions estro-progestatives topiques a effet systemique

Also Published As

Publication number Publication date
EP1515725A4 (en) 2005-09-21
ZA200410411B (en) 2007-06-27
TW200404548A (en) 2004-04-01
AR040333A1 (es) 2005-03-30
US7192956B2 (en) 2007-03-20
AU2003247608A1 (en) 2004-01-06
WO2004000801A2 (en) 2003-12-31
JP2005535624A (ja) 2005-11-24
CA2489847A1 (en) 2003-12-31
BR0312024A (pt) 2005-03-22
IL165396A0 (en) 2006-01-15
CN1662241A (zh) 2005-08-31
WO2004000801A3 (en) 2004-03-25
US20040006060A1 (en) 2004-01-08
CR7611A (es) 2006-05-30
MXPA04012421A (es) 2005-04-19
NO20045216L (no) 2005-01-24
KR20050013247A (ko) 2005-02-03
CO5680438A2 (es) 2006-09-29
RU2005101638A (ru) 2006-01-20
EP1515725A2 (en) 2005-03-23

Similar Documents

Publication Publication Date Title
ECSP055576A (es) Uso de derivados de ciclotiocarbamato en el tratamiento de las condiciones relacionadas con hormonas
ECSP055574A (es) Uso de derivados de tio-oxindol en el tratamiento de condiciones relacionadas con hormonas.
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
BR112019006227A2 (pt) métodos de tratamento de leiomioma uterino e endometriose
SV2004000061A (es) Moduladores del receptor glucocorticoide ref. 10118 amag/bb
ECSP034428A (es) Ciclopentanoindoles, composiciones conteniendo tales compuestos y su uso
AR049262A1 (es) Combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias
UY28150A1 (es) Agentes terapeuticos
UY32791A (es) Derivados de 17-hidroxi-17-pentafluoroetil-estra-4,9(10)-dien-11arilo, procedimientos para su preparación y su uso para el tratamiento de enfermedades
UY27188A1 (es) Uso de agonistas inversos de gabaa en combinación con agonistas parciales del receptor de nicotina, estrógenos, moduladores selectivos de estrógenos o vitamina e, para el tratamiento de trastornos cognitivos.
PE20211588A1 (es) Compuestos y sus usos para aliviar sintomas asociados a la menopausia
PE20020348A1 (es) Exemestano como agente quimiopreventivo
UY29626A1 (es) Moduladores no esteroides de receptores de progesterona
PE20070182A1 (es) Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona
CR10617A (es) Derivados de oxazolidona como moduladores pr
CR9627A (es) Cyanopyrrole-sulfonamide progesterone receptor modulators and uses thereof
PA8771801A1 (es) Heterociclos sulfonilados utiles para la modulacion del receptor de progesterona
UY29625A1 (es) Uso de moduladores no esteroides de receptores de progesterona
UY29624A1 (es) Moduladores no esteroides de receptor de progesterona
AR044450A1 (es) Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas
AR040188A1 (es) Estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva
ECSP109872A (es) Estratrienos 8-beta-sustituidos como estrógenos de acción selectiva
AR036227A1 (es) USO DE LIGANDOS SELECTIVOS PARA ERa PARA REGULAR LA FERTILIDAD.
Fernández et al. The administration of hCG or GnRH induce the formation of accessory corpora lutea
AR124650A2 (es) Geles nasales de liberación controlada de testosterona, métodos y sistemas aplicadores multidosis pre cargados para administración pernasal